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Prevalence of chronic kidney disease in adults in England: comparison of nationally 25 
representative cross-sectional surveys from 2003 to 2016 26 
Abstract 27 
Objectives: To identify recent trends in chronic kidney disease (CKD) prevalence in England and 28 
explore their association with changes in sociodemographic, behavioural and clinical factors. 29 
Design: Pooled cross-sectional analysis. 30 
Setting: Health Survey for England 2003, 2009/2010 combined, and 2016. 31 
Participants: 17,663 individuals (aged 16+) living in private households. 32 
Primary and secondary outcome measures: Prevalence of estimated glomerular filtration rate 33 
(eGFR) <60ml/min/1.73m2 and albuminuria (measured by albumin-creatinine ratio) during 34 
2009/2010 and 2016 and trends in eGFR between 2003 to 2016. eGFR was estimated using 35 
serum creatinine Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) and Modification 36 
of Diet in Renal Disease (MDRD) equations. 37 
Results: GFR<60ml/min/1.73m2 prevalence was 7.7% (95% CI: 7.1-8.4%), 7.0% (6.4- 7.7%), and 38 
7.3% (6.5-8.2%) in 2003, 2009/2010, and 2016, respectively.  Albuminuria prevalence was 8.7% 39 
(8.1-9.5%) in 2009/10 and 9.8% (8.7-10.9%) in 2016.  Prevalence of CKD G1-5 40 
(eGFR<60ml/min/1.73m2 or albuminuria) was 12.6% (11.8-13.4%) in 2009/2010 and 13.9% 41 
(12.8-15.2%) in 2016. Prevalence of diabetes and obesity increased during 2003-2016 whilst 42 
prevalence of hypertension and smoking fell. The age- and gender-adjusted odds ratio (OR) of 43 
eGFR<60ml/min/1.73m2 for 2016 vs 2009/10 was 0.99 (0.82-1.18) and fully-adjusted OR was 44 
1.13 (0.93-1.37). There was no significant period effect on the prevalence of albuminuria or CKD 45 
G1-5 from 2009/10 to 2016 in age and gender or fully-adjusted models.  46 
Conclusion: The fall in eGFR<60ml/min/1.73m2 seen from 2003 to 2009/10 did not continue to 47 
2016. However absolute CKD burden is likely to rise with population growth and ageing, 48 
particularly if diabetes prevalence continues to increase. This highlights the need for greater 49 
CKD prevention efforts and continued surveillance.  50 
 51 
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Article Summary 54 
Strengths and limitations of this study 55 
The study is based on robust survey methodology using standardised protocols over time and 56 
taking into account complex survey design to reduce response bias. 57 
Prevalence may be underestimated as residential care and hospitalised patients were excluded. 58 
Single measures of serum creatinine and albumin to creatinine ratio so no chronicity established  59 
  60 




Chronic kidney disease (CKD), defined and staged using estimated glomerular filtration rate 62 
(eGFR) and indicators of kidney damage such as albuminuria (1), is a global public health 63 
problem with high economic cost, morbidity and mortality (2-4). The Global Burden of Disease 64 
study has shown rising global impact, largely due to population growth and ageing (4).    65 
It is important to assess trends in CKD to inform prevention and health care planning. There are 66 
variable data on CKD time trends. In the United Kingdom (UK), CKD G3-5 prevalence fell in 67 
England between 2003 and 2009/2010 whilst remaining stable in Scotland between 2004 and 68 
2009/2010 (5,6). United States (US) studies using the National Health and Nutrition Examination 69 
(NHANES) found an increase in CKD prevalence from 1988 to 2004, followed by stabilisation 70 
between 2003/2004 and 2011/2012 (7,8). Other studies found CKD prevalence increased in 71 
Japan from 1974 to 2002 and in Finland between 2002 and 2007; remained stable in Norway 72 
from 1995 to 2008; and decreased in Korea from 2005 to 2007 (9-12). These differences in time 73 
patterns may reflect true changes, random variation, or be a result of methodological and 74 
analytical differences across studies. Some projection studies have suggested an increase in CKD 75 
burden in the coming decade and beyond, which may be expected given the continued rise in 76 
obesity and diabetes prevalence, and ageing population (13-15). 77 
There is a lack of studies assessing CKD prevalence in recent years. It is important to examine if 78 
the earlier fall in CKD prevalence in the UK has continued and to investigate changes in 79 
albuminuria prevalence, given its prognostic importance (16).  This study extends previous 80 
analyses between 2003 and 2009/2010 to examine time trends in CKD prevalence in England 81 
using the nationally representative Health Survey for England (HSE) in 2016, and to what extent 82 
any changes were explained by demographic and risk factor changes. 83 
  84 
Materials and methods 85 
Study population 86 
The HSE is an annual survey of a nationally representative sample of individuals living in private 87 
households in England. The survey, conducted by trained interviewers, collects detailed 88 
information on sociodemographic characteristics, physical health, lifestyle behaviours, mental 89 
health and wellbeing, and anthropometric measurements, in order to explore changes in the 90 
health and lifestyles of people in England. This is supplemented with clinical assessment by 91 
trained nurses (e.g. for blood pressure, medication) and with blood and urine sampling.  Kidney 92 
function tests were measured in adults (aged 16+) in 2003 (serum creatinine from stored 93 
samples, 2009/2010 and 2016 (serum creatinine, cystatin C and urinary albumin/creatinine 94 
ratio).  95 
Survey participants were selected each year using a multi-stage stratified probability sampling 96 
design. Full details of the methodology including sample design, response rates, and weighting 97 
can be found in the 2003, 2009, 2010 and 2016 Health Survey Reports (17-20). There were 98 
household response rates of 73%, 68%, 66%, and 55% for the 2003, 2009, 2010, and 2016 HSE, 99 
respectively. A total of 14,836 adults were interviewed in the 2003 HSE, 4645 adults in 2009, 100 
8420 in 2010, and 8011 in 2016. 101 
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The current study uses data from participants aged ≥16 years who had valid serum creatinine or 102 
valid urine creatinine and albumin test results. The population for the current study was 17633 103 
individuals which included 7844/14,836 (53%), 6053/13,065 (46%), and 3766/8011 (47%) 104 
individuals from the 2003, 2009/2010, and 2016 HSE respectively for analyses using creatinine. 105 
Analyses for albuminuria used all available data at each time point and comprised 7633 and 106 
4361 individuals from the 2009/2010 and 2016 HSE, respectively. Since HSE 2009 and 2010 were 107 
conducted at close time points, data from these surveys were combined to increase sample 108 
study sample size, allowing sufficient power to conduct the analyses, as was done in a previous 109 
study (5). Each survey year consisted of a new sample of participants and there was no double 110 
counting in our sample. 111 
Kidney function measures  112 
Serum creatinine was assayed using an isotope dilution mass spectrometry (IDMS) traceable 113 
enzymatic assay on a Roche Modular analyser in 2009/2010 and on a Roche Cobas analyser in 114 
2016 in a single laboratory: the Clinical Biochemistry Department at the Royal Victoria Infirmary 115 
(RVI), Newcastle upon Tyne. Details of laboratory analysis, internal quality control and external 116 
quality assurance are provided in the 2009/2010 and 2016 documentation (18-20). The same 117 
methods were applied to the 2003 HSE samples. The 2003 HSE samples had been stored, frozen 118 
at -40 degree Celsius, and then thawed for measurement in 2010. A correction factor was 119 
applied to 2003 samples to account for the effect of freezing on creatinine levels (5).  A 120 
conversion equation derived by scientists at the RVI was then applied to the corrected 2003 121 
creatinine values, as well as 2009 and 2010 samples, to account for differences in analysers 122 
between earlier years and 2016 and allow direct comparisons. Serum creatinine concentration 123 
was used to estimate GFR using the CKD EPI equations (21). eGFR is categorised as 124 
<60ml/min/1.73m2(CKD G3-5) and <45ml/min/1.73m2 (G3b-5). The CKD EPI equation was used 125 
as this is more accurate than the MDRD equation and is recommended for use in the UK (22).        126 
Albuminuria was measured on a single random urine sample at the RVI.  Urine albumin was 127 
measured by immunoassay (on a Siemens Nephelometer analyser in 2009, on a Roche Modular 128 
analyser in 2010 and on a Roche Cobas analyser in 2016).  Urine creatinine was measured by 129 
colorimetric assay (Jaffe method on an Olympus analyser, Jaffe method on a Roche Modular 130 
analyser, and enzymatic method on a Roche Cobas analyser in 2009, 2010, and 2016, 131 
respectively). Conversion equations (derived at the RVI) were applied to 2009 and 2010 urinary 132 
albumin and creatinine values to account for changes in analysers between 2009/2010 and 133 
2016. Albuminuria was defined as urinary albumin to creatinine ratio (uACR) >3mg/mmol (23).  134 
CKD G1-5 was defined as eGFR<60 and/or albuminuria and categorized as moderate, high, or 135 
very high risk based on combinations of eGFR and uACR in the KDIGO classification system (23). 136 
Sociodemographic characteristics 137 
Age was grouped into five categories: 16-34, 35-54, 55-64, 65-74, and 75+ years. Ethnicity was 138 
grouped into four categories: White, South Asian, Black, and other. Socioeconomic factors 139 
included occupation, car ownership, and housing tenure. Occupation was classified using 140 
National Statistics Socioeconomic Classification (NS-SEC) and grouped into three categories: high 141 
(managerial and professional occupations), middle (intermediate occupations), and low (routine 142 
and manual occupations). Housing tenure was divided into two groups: owner and rented. 143 
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Education was grouped as degree level (NVQ4/NVQ5/Degree or equivalent), below degree, and 144 
no qualification.  145 
Clinical and behavioural variables 146 
Clinical and behavioural  factors included smoking (never, ex- smoker, current smoker) and body 147 
mass index (BMI; normal/underweight [<25kg/m2], overweight [25-29.9kg/m2], obese 148 
[>=30kg/m2], waist circumference (low: <94 cm for males, <80 cm for females; high: 94-102cm 149 
for males, 80-88cm females; very high: >102cm for males, >88cm for females). For South Asian 150 
men, the waist circumference was classified as: low: <90; high: 90–102; and very high: >102 cm 151 
(24). 152 
Clinical variables included cholesterol level (high density lipoprotein [HDL] and total cholesterol) 153 
from non-fasting blood samples; self-reported doctor-diagnosed diabetes, survey-diagnosed 154 
diabetes (glycated haemoglobin [HBA1c] ≥6.5% at nurse survey examination in those not 155 
reporting a diagnosis), total diabetes (doctor + survey-diagnosed);  self-reported doctor-156 
diagnosed hypertension, survey-diagnosed hypertension (systolic blood pressure ≥140mmHg 157 
and/or diastolic ≥90mmHg in those not reporting a doctor diagnosis or on medication for 158 
hypertension at the survey examination) (19), and total (doctor + survey-diagnosed) 159 
hypertension. Self-reported prescribed medication was any anti-hypertensive medication or 160 
lipid lowering agents. 161 
Where blood pressure was not raised but anti-hypertensive medication data were missing, we 162 
assumed such participants did not have hypertension.  163 
 164 
Statistics 165 
Descriptive statistics were used to compare sociodemographic, clinical and behavioural 166 
characteristics, and kidney function measures over time, both between 2009/10 and 2016 and a 167 
trend for 2003-2016. Chi-squared tests were used to test differences for categorical variables 168 
and Somers’ D rank tests were used to test for non-normally distributed continuous variables. 169 
Normally distributed variables, including total and HDL cholesterol levels, were compared using 170 
t-tests. 171 
Multivariable logistic regression models (including age and gender) were used to examine 172 
associations between CKD G3-5 (eGFR<60ml/min/1.73m2) and time period (fitted as 2003, 173 
2009/2010 and 2016), sociodemographic, clinical and behavioural variables. Similar models 174 
were applied to CKD G1-5 and albuminuria. We used complete case analysis for the primary 175 
modelling as the extent of missing data was below 10% for any variable (25). We repeated the 176 
analysis using all available data in each regression model, rather than complete case analysis.  177 
All analyses were conducted using STATA 14 SE and took account of the complex sampling 178 
method (including stratification and clustering due to the two-stage sampling design) and 179 
sampling weights (blood or urine as appropriate, which incorporate non-response at all stages 180 
including interview and nurse assessment to address differences in subpopulations and maintain 181 
national representativeness) through the use of the survey data commands.  182 
Patient and Public Involvement (PPI):  183 
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We did not directly include PPI in this study.  184 
 185 
Results 186 
The study population consisted of 17663 adults with serum creatinine test results and 11994 187 
adults with valid urinary creatinine and albumin test results.  188 
Survey characteristics  189 
Gender and car ownership distribution were similar, while the proportion of people with older 190 
age, highest level of education, higher NS-SEC, and diabetes (both doctor- and survey-191 
diagnosed) increased from 2003 to 2016 (Table1). There was a decrease in the proportion of 192 
people of white ethnicity, home owners, current smokers, doctor-diagnosed and total 193 
hypertension. There were increases in median levels of glycated haemoglobin, HDL cholesterol, 194 
BMI and waist circumference and decreases in systolic and diastolic blood pressure and total 195 
cholesterol over the time period, and the changes were present from 2009/10 to-2016 (except 196 
for diastolic BP and BMI).  There was an increase in the proportion of people with doctor-197 
diagnosed CKD between 2009/2010 and 2016, though it remained low (Table 1). 198 
Kidney function measures  199 
Table 2 shows that there were small increases in median serum creatinine levels and 200 
concomitant decreases in eGFR levels between 2003-16, largely reflected in changes in the 201 
balance of eGFR <60-89ml/min/1.73m2 and >90 ml/min/1.73m2. eGFR <60 ml/min/1.73m2 202 
prevalence was 7.7% (95% CI: 7.1-8.4%), 7.0% (6.4- 7.7%), and 7.3% (6.5-8.2%) in 203 
2003,2009/2010 and 2016, respectively. Differences were not statistically significant.  There was 204 
little change in eGFR<45ml/min/1.73m2.  205 
Figure 1 shows the pattern of eGFR<60ml/min/1.73m2 by age and gender from 2009/10 to 206 
2016. Women had a higher prevalence and consistent pattern of no change in any age group. 207 
The age pattern was more variable for men. 208 
Albuminuria prevalence was 8.7% (8.1-9.5%) in 2009/10 and 9.8% (8.7-10.9%) in 2016.This was 209 
not statistically significant and median urinary albumin levels fell (Table 2). Albuminuria 210 
prevalence increased with age with a slight J shape (Figure 2). In those with both urine and 211 
blood results across surveys, 88% of albuminuria was observed in people with eGFR>60 (85% in 212 
those aged 35 and over) and 16% had doctor diagnosed diabetes (21% in those over 35). 213 
Prevalence of CKD G1-5 was 12.6% (11.8-13.4%) in 2009/2010 and 13.9% (12.8-15.2%) in 2016 214 
(Table 2). There was no significant increase in CKD 1-5 prevalence overall or by any risk 215 
category, or by age group, diabetes status, or obesity. 216 
 217 
Multivariable analyses  218 
Regression models showed no significant differences in risk of eGFR<60ml/min/1.73m2 for 2016 219 
compared with 2009/2010 (Table 3). The odds ratio (OR) of having eGFR<60ml/min/1.73m2 in 220 
2016 compared with 2009/10 was 0.99 (0.82-1.18) in age- and gender-adjusted models and 1.13 221 
(0.93-1.37) in fully-adjusted models. There was no significant change in albuminuria prevalence 222 
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in age- and gender- [OR: 1.05 (0.86-1.29)] or fully-adjusted models [1.09 (0.88-1.36)] (Table 4). 223 
The OR for having CKD 1-5 were 1.03 (0.87-1.21) in age- and gender-adjusted models and 1.10 224 
(0.92-1.31) in fully-adjusted models (Table 5). 225 
Sensitivity analyses using all available data for each model and outcome according to missing 226 
data found very similar results (see appendices 1-3). The period effect estimates in these models 227 
were consistent with the complete case models for all outcomes, though with narrower 228 
confidence intervals due to the larger sample size and statistical power. 229 
Discussion 230 
These nationally representative population-based studies in England have shown that the 231 
previous findings of a significant fall in CKD Stage 3-5 prevalence from 2003 to 2009/2010 has 232 
not continued to 2016. There were no significant changes in prevalence of albuminuria and CKD 233 
G1-5 between 2009/10 and 2016. 234 
Population risk factors for CKD changed in different directions in 2009/10 to 2016, notably with 235 
increases in prevalence of diabetes, proportion at older age and decreases in hypertension and 236 
smoking. There were also changes in socioeconomic status and prevalence of ethnic minorities 237 
which could influence CKD prevalence (26, 27).  The pattern of CKD prevalence is likely to reflect 238 
the balance of such countervailing CKD risk factors. Adjustment has been made for all these 239 
factors in assessing period changes in CKD prevalence.   240 
A key finding for CKD prevention were the changes in population blood pressure levels and 241 
hypertension prevalence which may partly be due to the decline in population salt consumption 242 
(28, 29). Changes in blood pressure management in patients with known hypertension may also 243 
be an important factor, which we did not directly address due to limited numbers in the surveys 244 
and incomplete antihypertensive medication details. The study period coincided with the 245 
introduction in 2006 of the Quality Outcomes Framework (QoF) in England (an incentivised 246 
system for performance management of patients with diabetes, hypertension, and CKD),  and 247 
the NHS Health Check for 40-74 year olds (a national population programme with cardiovascular 248 
disease (CVD) risk factor assessment including blood pressure measurement (30, 31).  A 249 
systematic review of the impact of QoF on long-term conditions found some limited evidence 250 
for improved care (32). The NHS Health Check led to small reductions in blood pressure in non-251 
randomised comparisons of NHS Health Check attendees and non-attendees and to increased 252 
prescription of antihypertensive agents (33, 34).  253 
The increase in HDL cholesterol and decrease in total cholesterol over time may reflect the 254 
wider use of statins for the primary and secondary prevention of CVD. HDL was associated with 255 
reduced CKD prevalence in adjusted analyses, though the effect of statins in preventing CKD 256 
progression is uncertain (35,36,37). 257 
A countervailing driver that would increase population CKD levels is the rising prevalence of 258 
diabetes, both diagnosed and undiagnosed. For those with diagnosed diabetes, the National 259 
Diabetes Audit for 2016-17 found slight improvement in HBA1c control (though it was poor 260 
overall in patients with Type 1 diabetes, mirroring the QoF review findings (38, 39). Urine ACR 261 
measurement was low in both types of diabetes and declined from 2011/12 to 2016/2017 with 262 
large variation between general practices (38). The National CKD Audit also confirmed poor 263 
recording of uACR in patients with diabetes and CKD and found it to be even poorer in those 264 
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with diagnosed hypertension (40).  Lack of identification of albuminuria is of concern as it is a 265 
major risk factor for both CKD progression and incident cardiovascular disease and there is 266 
effective treatment available with RAS inhibition (41).  267 
To our knowledge this study presents the most recent data on actual trends in CKD in a free-268 
living general population. Murphy et al used serial US NHANES data from the late 1990s to 2012 269 
and found that prevalence of CKD G3-4 and CKD G1-4 increased to the mid-2000s but then 270 
stabilised, overall and in age, gender, ethnic, and diabetes sub- groups except for non-Hispanic 271 
Blacks (8). This was ascribed to improved management of both hypertension (42) and diabetes 272 
despite rising diabetes prevalence per se (43). Hallan et al analysed the Health Survey of Nord –273 
Trondelag (HUNT) from 1995-7 to 2006-8 and found that the prevalence of CKD G1-5 was stable, 274 
which was ascribed to improved blood pressure control and to a lesser degree to lower total 275 
cholesterol (there was no change in HDL), and greater physical activity, offset by moderate 276 
increases in obesity and diabetes (11).    277 
The survey showed that estimated CKD prevalence was substantially higher than doctor-278 
diagnosed CKD (the latter being 1.1% to 1.8% for 2009/2010 and 2016, respectively). This may 279 
be due to lack of diagnosis (insufficient testing in the population), or patients have not been told 280 
or cannot recall being told by their doctor that they have CKD, as well as a small overestimation 281 
in the survey due to lack of confirmed chronicity. 282 
Study strengths and limitations 283 
Strengths of the study include the large, nationally representative population, as well as robust 284 
survey methodology using standardised protocols (including the same laboratory and use of 285 
conversion equations to account for changes in assays, analysers, and methods over time). The 286 
complex survey design was taken into account and non-response blood/urine weights used to 287 
reduce response bias and ensure national representativeness.  This is important, as overall HSE 288 
survey response rates have declined with time. Time trend analysis was able to take into 289 
account a range of socio-demographic, behavioural and clinical factors that were measured in a 290 
standardised way across the surveys. We were able to assess changes in uACR, which is often 291 
not measured in studies of CKD prevalence.  292 
Limitations included the relatively short time period and fewer blood and urine samples in 2016, 293 
limiting the power of the study. Some data items were incomplete, there still is no consensus on 294 
exactly how multiple imputation should be used with survey weighted data especially when the 295 
weighting is complex and multi-stage as in HSE (44). Moreover, it is recommended that 296 
imputation is performed by the survey providers rather than secondary users. Another 297 
limitation was that the survey, as do all national health surveys, excluded those in residential 298 
care or hospitalised patients, which may include some individuals with CKD and therefore 299 
underestimates prevalence - especially of more severe CKD.  On the other hand, CKD prevalence 300 
may have been overestimated as a single blood sample was tested in each survey, meaning 301 
chronicity of reduced eGFR levels could not be confirmed (as required by the KDIGO definition) 302 
and previous studies have found fluctuations in creatinine can have a strong effect on CKD 303 
prevalence (45). Furthermore, an isolated low eGFR could represent an episode of acute kidney 304 
injury, though this is unlikely for participants of a health survey. A single uACR is also a poor 305 
indicator of albuminuria, as data from NHANES suggest a third of initially increased uACR results 306 
may be normal if repeat testing is performed (7). ACR was measured using a random sample 307 
rather than early morning urine which may increase prevalence (orthostatic proteinuria) 308 
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especially in the young, females, and those without hypertension or diabetes but this should not 309 
affect trends (46). The cross-sectional nature of the survey is a limitation as it lacks chronicity 310 
and restricts the ability to infer any causal relationships from the associations identified. 311 
Although primary care databases are a suitable source of repeated measurements, testing per 312 
se and repeat testing are selective and restricted to those accessing healthcare and therefore 313 
findings may not be representative of the general population. Age was modelled as a categorical 314 
term and not linearly as data governance policy at the time of analyses precluded the availability 315 
of individual age data to download from the UK Data Archive, so given the strong effect of age it 316 
is possible there is residual confounding. There were no data on prevalent CVD, a cause and 317 
consequence of CKD, so adjustment for trends in this was not possible.  An important limitation 318 
was the lack of data on cystatin C based eGFR trends. Estimation of GFR using an equation that 319 
includes serum creatinine and cystatin C gives a more accurate result than one based on 320 
creatinine alone (47). We measured cystatin C but the analysis suggested that differences in 321 
assay standardisation (non-standardised in 2009/2010 and standardised in 2016) accounted for 322 
a large rise observed in cystatin C concentration. The assessment of quality of care of key 323 
groups, such as those with diagnosed diabetes in HSE, was limited by numbers. There were 324 
limited data to assign likely cause(s) of CKD. Additionally,, the analysis pertains to the adult 325 
population of England and may not be generalisable to other populations with different socio-326 
demographic or underlying risk factor patterns. Finally, we used the correction factor for Black 327 
ethnicity in the CKDEPI and MDRD equations to calculate eGFR. This may have introduced some 328 
bias as the correction factor was derived using US populations which may not be accurate for UK 329 
populations. However, our finding of lower prevalence of CKD in South Asian and African-330 
Americans/Afro-Caribbean compared with Caucasians is consistent with studies that report 331 
ethnic minority groups having lower or similar CKD prevalence despite higher incidence of end 332 
stage renal disease (48-50). 333 
 334 
The finding of stable CKD prevalence may have important implications globally due to the 335 
ascending rank of CKD as a leading Global Burden of Disease cause of disability-adjusted life 336 
years (DALYs) and projected population growth and ageing, both of which will increase absolute 337 
CKD prevalence (51,52). Greater efforts are needed to prevent eGFR decline both in the general 338 
population and in those with CKD to reduce CKD incidence and its progression, through 339 
hypertension prevention, detection and control, obesity and diabetes prevention, and better 340 
management of existing diabetes. The under-ascertainment of albuminuria in patients with 341 
diabetes is of concern and merits further efforts and consideration of testing in patients with 342 
hypertension.  343 
 344 
Conclusion 345 
In this nationally representative population-based study, the previously reported trend of 346 
decreasing CKD prevalence between 2003 and 2009/2010 did not continue to 2016 despite 347 
favourable changes in hypertension prevalence. Further studies in the HSE series including using 348 
cystatin C and albuminuria are needed to monitor and better understand CKD trends and assess 349 
prevention efforts, and better understand mechanisms of change. 350 
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Table 1: Change in proportion of sociodemographic, health and lifestyle variables between 2003, 2009/2010 and 2016  
 









2003 to 2016 
trend test 
Age 
16-34 2423 (31.0%) 1847 (30.6%) 1145 (30.4%) 0.334 0.081 
34-54 2787 (35.7%) 2129 (35.2%) 1272 (33.8%)   
55-64 1126 (14.4%) 886 (14.7%) 542 (14.4%)   
65-74 812 (10.4%) 639 (10.6%) 457 (12.1%)   
75+ 662 (8.5%) 539 (8.9%) 352 (9.3%)   
Missing¥ 0 0 3   
Ethnicity 
White 7226 (92.5%) 5461 (90.5%) 3271 (87.0%) 0.002 <0.001 
South Asian 333 (4.3%) 265 (4.4%) 299 (7.9%)   
Black 144 (1.8%) 159 (2.6%) 100 (2.7%)   
Other 108 (1.4%) 149 (2.5%) 92 (2.4%)   
Missing 0 7 3   
Gender 
Male 3793 (48.6%) 2961 (49.0%) 1850 (49.1%) 0.935 0.529 
Female 4017 (51.4%) 3080 (51.0%) 1917 (50.9%)   
Missing 0 0 0   
  




Degree 1375 (17.6%) 1363 (22.6%) 1133 (30.1%) <0.001 <0.001 
Below degree 4551 (58.4%) 3442 (57.0%) 1928 (51.2%)   
None 1874 (24.0%) 1230 (20.4%) 703 (18.7%)   
Missing 8 4 3   
NS-SEC 
Highest  2514 (33.7%) 1988 (35.0%) 1289 (37.0%) 0.001 <0.001 
Middle 1674 (22.4%) 1263 (22.2%) 877 (25.1%)   
Lowest 3273 (43.9%) 2424 (42.7%) 1322 (37.9%)   
Missing 245 233 143   
Car ownership 
Yes 6460 (82.7%) 4948 (81.9%) 3080 (81.8%) 0.914 0.424 
No 1348 (17.3%) 1092 (18.1%) 687 (18.2%)   
Missing 2 1 1   
Tenure 
Own 5908 (76.6%) 4184 (70.2%) 2467 (66.4%) 0.039 <0.001 
Rent 1805 (23.4%) 1776 (29.8%) 1249 (33.6%)   



















Missing 12 8 1   
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Body mass index 
Normal/underweight 2820 (38.5%) 1997 (36.0%) 1319 (38.1%)   
Overweight 2865 (39.1%) 2128 (38.4%) 1229 (35.5%)   
Obese 1637 (22.4%) 1425 (25.7%) 917 (26.5%) 0.093 0.006 
Missing 478 497 328   
Body mass index 
(mean, SD) 
 26.8 (4.9) 27.2 (5.2) 27.1 (5.4) 0.027 0.006 
Waist circumference 
Low  3020 (39.3%) 2184 (36.6%) 1343 (36.5%) 0.982 0.002 
High  1969 (25.6%) 1452 (24.4%) 903 (24.6%)   
Very high  2703 (35.1%) 2325 (39.0%) 1433 (38.9%)   












Missing 0 0 0   
Survey-diagnosed 
diabetes 
      
No (HBA1c <6.5%) 7401 (96.2%) 5636 (94.5%) 3399 (91.8%) <0.001 <0.001 



















Missing 0 0 0   






 5.3 (0.7) 5.6 (0.7) 5.7 (0.8) 0.002 <0.001 
HDL cholesterol 
(mmol/L) (mean, SD) 
 1.5 (0.4) 1.5 (0.4) 1.7 (0.5) <0.001 <0.001 
Total cholesterol 
(mmol/L) (mean, SD) 



































Missing 5 1 1   
Systolic blood pressure 
(mmHg) (mean, SD) 
Diastolic blood pressure 
































Missing - 0 0   
*weighted to be nationally representative in each time period. Percentages are of complete data. SD= standard deviation. ¥number of missing 
observations for each variable (not weighted). 
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Table 2: Change in renal function markers between 2003, 2009/2010 and 2016 








Blood samples  N=7844 (95% CI) N=6053 (95% CI) N=3766 (95% CI)   
Serum creatinine  
(mol/L) 
Median 76.9   77.2   79.0   <0.001 <0.001 
LQ to UQ 67.3 to 87.5  66.9 to 88.5  69.0 to 91.0    
CKD EPI creatinine 
eGFR 
(mL/min/1.73m2)  
Median 93.3   92.6   89.8   <0.001 <0.001 
LQ to UQ 77.8 to 108.3  78.1 to 106.8  75.9 to 103.1    













































Urine test samples     N=7633  N=4361    
Urine albumin 
(mg/L) 
Median   4.9   4.0   <0.001 0.084 
LQ to UQ   4.9 to 9.0  3.0 to 10.0    
Urine creatinine 
(mmol/L) 
Median   9.9   9.5   0.218 0.274 
LQ to UQ   5.3 to 14.9  5.3 to 14.4    
Albuminuria - 
Urinary albumin to 
Creatinine ratio 
(mg/mmol) 
< 3   6966 (91.3%)  3915 (90.3%)    













No   6675 (87.5%)  3755 (86.1%)    
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Table 3: Prevalence of eGFR<60ml/min/1.73m2 by CKD EPI creatinine equation over time with adjustment for sociodemographic, behavioural and 
clinical factors (N=16118 in all models**) 
 Variable Category 
Prevalence 
of CKD (%) 
Unadjusted 
OR (95% CI) 
Age- and gender-
adjusted  
OR (95% CI) 
Sociodemographic 
adjusted  
OR (95% CI) 
Sociodemographic, 
behavioural & 
clinical adjusted OR 
(95% CI) 
Fully adjusted 
OR (95% CI) 
HSE Year 
2003 6.9 1.13 (0.97-1.31) 1.22 (1.04-1.43) 1.19 (1.01-1.39) 1.22 (1.03 -1.43) 1.28 (1.09-1.51) 
2009-2010 6.2 1 1 1 1 1 
2016 6.7 1.08 (0.90-1.29) 0.99 (0.82-1.18) 1.00 (0.84-1.21) 1.00 (0.83 -1.20) 1.13 (0.93-1.36) 
Age 
16-34 0.0 0.02(0.00-0.05) 0.02 (0.00-0.05) 0.02 (0.00-0.05) 0.02 (0.01-0.07) 0.02 (0.01-0.07) 
35-54 1.5 0.22 (0.17-0.30) 0.22 (0.17-0.30) 0.23 (0.17-0.30) 0.26 (0.19-0.34) 0.26 (0.19-0.34) 
55-64 6.3 1 1 1 1 1 
65-74 17.9 3.24 (2.65-3.97) 3.26 (2.67-3.99) 3.16 (2.58-3.87) 2.96 (2.41-3.64) 2.90 (2.36-3.56) 
75+ 42.8 11.17 (9.11-13.70) 11.17 (9.11-13.70) 10.57 (8.58-13.03) 9.64 (7.76-11.97) 9.44 (7.59-11.75) 
Gender 
Male 5.7 1 1 1 1 1 
Female 7.6 1.36 (1.21-1.53) 1.21 (1.06-1.38) 1.17 (1.02-1.33) 1.23 (1.07-1.42) 1.44 (1.23-1.67) 
Ethnicity 
White 7.1 1  1 1 1 
South 
Asian 
2.9 0.40 (0.25-0.64)  1.40 (0.85-2.32) 1.25 (0.75-2.08) 1.21 (0.73-1.98) 
Black 1.7 0.22 (0.09-0.52)  0.35 (0.14-0.89) 0.30 (0.11-0.78) 0.34 (0.13-0.89) 
Other 1.7 0.23 (0.10-0.56)  0. 91 (0.43-1.93) 0.86 (0.39-1.91) 0.86 (0.39-1.90) 
Tenure 
Own 7.0 1  1 1 1 




2.8 1  1 1 1 
Below 
degree 
4.8 1.74 (1.38-2.20)  1.25 (0.98-1.59) 1.20 (0.94-1.53) 1.17 (0.91-1.49) 
None 15.9 6.60 (5.21-8.35)  1.43 (1.11-1.86) 1.34 (1.03-1.75) 1.28 (0.98-1.67) 
Smoking 
Never 6.1 1   1 1 
Ex-smoker 11.1 1.94 (1.69-2.21)   1.03 (0.88-1.20) 1.02 (0.88-1.19) 









4.1 1   1 1 
Overweight 
(25-30) 
7.6 1.90 (1.63-2.21)   1.24 (1.05-1.48) 1.13 (0.95-1.34) 
Obese 
(>30) 








- 1.09 (1.03-1.15)    1.02 (0.95-1.09) 
Diabetes 
No 5.7 1   1 1 
Yes 20.7 4.31 (3.65-5.11)   1.55 (1.27-1.88) 1.33 (1.08-1.62) 
Hypertension 
No 3.1 1   1 1 




No 5.0 1    1 
Yes 
22.4 5.55 (4.82-6.38)    1.39 (1.16-1.67) 
*significant associations are marked bold. Age- and gender-adjusted models regressed CKD on HSE year, age and gender; Sociodemographic adjusted 
models regressed CKD on HSE year, age, gender, ethnicity, tenure, education; Sociodemographic, behavioural & clinical adjusted models regressed CKD 
on HSE year, age, gender, ethnicity, tenure, education, smoking, BMI, diabetes and hypertension; Fully adjusted models regressed CKD on HSE year, age, 
gender, ethnicity, tenure, education, smoking, BMI, diabetes, hypertension, HDL, total cholesterol.**Complete case analysis (n=16118). CKD 
prevalence slightly less than shown in Table 2. 
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Table 4: Prevalence of albuminuria over time with adjustment for sociodemographic, behavioural and clinical factors (N=8312 in all models) 





OR (95% CI) 
Age- and gender-
adjusted 
OR (95% CI) 
Sociodemographic 
adjusted 
OR (95% CI) 
Sociodemographic, 
behavioural & clinical 
adjusted 
OR (95% CI) 
Fully adjusted 
OR (95% CI) 
HSE Year 
2003 - - - - - - 
2009-2010 7.5 1 1 1 1 1 
2016 8.1 1.09 (0.89-1.32) 1.05 (0.86-1.29) 1.06 (0.86-1.30) 1.05 (0.85-1.29) 1.09 (0.88-1.36) 
Age 
16-34 6.4 0.78 (0.57-1.07) 0.80 (0.58-1.10) 0.72 (0.52-0.99) 1.05 (0.76-1.47) 1.11 (0.78-1.57) 
35-54 5.3 0.64 (0.50-0.82) 0.65 (0.50-0.83) 0.64 (0.50-0.82) 0.79 (0.60-1.02) 0.81 (0.62-1.06) 
55-64 8.1 1 1 1 1 1 
65-74 11.7 1.50 (1.16-1.96) 1.51 (1.16-1.96) 1.49 (1.13-1.95) 1.35 (1.03-1.78) 1.31 (0.99-1.73) 
75+ 17.9 2.47 (1.87 -3.25) 2.42 (1.83 -3.19) 2.34 (1.75-3.12) 1.86 (1.38-2.52) 1.79 (1.32-2.42) 
Gender 
Male 6.1 1 1 1 1 1 
Female 9.4 1.58 (1.33-1.88) 1.52 (1.28-1.81) 1.50 (1.26-1.80) 1.62 (1.35-1.95) 1.70 (1.39-2.07) 
Ethnic 
White 7.8 1  1 1 1 
South Asian 8.3 1.07 (0.68-1.69)  1.38 (0.88-2.18) 1.35 (0.85-2.16) 1.33 (0.84-2.10) 
Black 5.0 0.62 (0.30-1.27)  0.69 (0.33-1.44) 0.64 (0.29-1.40) 0.68 (0.32-1.45) 
Other 6.2 0.78 (0.37-1.66)  1.00 (0.47-2.12) 0.90 (0.43-1.86) 0.93 (0.45-1.92) 
Tenure 
Own 7.3 1  1 1 1 
Rent 8.8 1.24 (1.00-1.52)  1.43 (1.14-1.78) 1.31 (1.04-1.66) 1.30 (1.03-1.64) 
Education 
Degree level 5.2 1  1 1 1 
Below degree 7.7 1.53 (1.19-1.97)  1.44 (1.12-1.85) 1.33 (1.03-1.72) 1.32 (1.03-1.71) 
None 11.4 2.35 (1.79-3.08)  1.43 (1.07-1.91) 1.26 (0.94-1.69) 1.24 (0.93-1.66) 
Smoking 
Never 7.0 1   1 1 
Ex-smoker 8.9 1.30 (1.06-1.60)   1.10 (0.89-1.35) 1.09 (0.88-1.34) 
Current 
smoker 
8.2 1.19 (0.93-1.53)   1.20 (0.91-1.58) 1.17 (0.88-1.56) 




Normal (<25) 7.5 1   1 1 
Overweight 
(25-30) 
6.8 0.91 (0.73-1.13)   0.82 (0.65-1.02) 0.78 (0.62-0.98) 








  0.94 (0.86-1.03)    1.04 (0.94-1.15) 
Diabetes 
No 6.8 1   1 1 
Yes 19.8 3.39 (2.72-4.23)   2.31 (1.81-2.95) 2.06 (1.59-2.66) 
Hypertension 
No 5.5 1   1 1 




No 6.5 1    1 
Yes 16.1 2.75 (2.26-3.35)    1.46 (1.10-1.93) 
 *significant associations are marked bold. 
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of CKD 1-5 
(%)  
Unadjusted 
OR (95% CI) 
Age- and gender-
adjusted 
OR (95% CI) 
Sociodemographic 
adjusted 




OR (95% CI) 
Fully adjusted 




12.2 1 1 1 1 1 
2016 13.2 1.09 (0.93 -1.27) 1.03 (0.87-1.21) 1.03 (0.88-1.22) 1.03 (0.87-1.22) 1.10 (0.92-1.31) 
Age 
16-34 6.5 0.48 (0.36-0.64) 0.49 (0.37-0.65) 0.44 (0.33-0.59) 0.65 (0.48-0.88) 0.68 (0.50-0.93) 
35-54 6.5 0.48 (0.39-0.59) 0.48 (0.39-0.60) 0.48 (0.39-0.59) 0.58 (0.46-0.72) 0.59 (0.47-0.74) 
55-64 12.7 1 1 1 1 1 
65-74 24.2 2.20 (1.79-2.70) 2.21 (1.80-2.72) 2.18 (1.76-2.70) 2.03 (1.63-2.53) 1.97 (1.58-2.45) 
75+ 48.6 6.50 (5.25-8.05) 6.44 (5.20-7.99) 6.24 (5.00-7.79) 5.37 (4.25-6.77) 5.18 (4.09-6.56) 
Gender 
Male 10.1 1 1 1 1 1 
Female 15.1 1.59 (1.39-1.81) 1.49 (1.29 -1.72) 1.46 (1.26-1.70) 1.60 (1.37-1.87) 1.72 (1.46-2.03) 
Ethnic 
White 13.0 1  1 1 1 
South 
Asian 
10.7 0.80 (0.51-1.27)  1.39 (0.88-2.19) 1.33 (0.83-2.12) 1.28 (0.81-2.04) 
Black 5.3 0.38 (0.19-0.75)  0.49 (0.22-1.07) 0.43 (0.18-1.03) 0.47 (0.20-1.08) 
Other 7.3 0.53 (0.27-1.03)  0.94 (0.48-1.83) 0.86 (0.45-1.67) 0.90 (0.46-1.72) 
Tenure 
Own 12.7 1  1 1 1 




7.6 1  1 1 1 
Below 
degree 
11.5 1.58 (1.28-1.95)  1.40 (1.13-1.73) 1.29 (1.04-1.59) 1.28 (1.03-1.58) 
None 23.1 3.65 (2.92-4.56)  1.45 (1.14-1.84) 1.27 (1.00-1.62) 1.25 (0.98-1.59) 
Smoking 
Never                                           11.3 1   1 1 
Ex-
smoker 
17.1 1.62 (1.39-1.88)   1.15 (0.97-1.36) 1.14 (0.96-1.35) 










10.4 1   1 1 
Overweig
ht (25-30) 
12.3 1.20 (1.00-1.43)   0.96 (0.79-1.17) 0.89 (0.73-1.09) 
Obese 
(>30) 




- 0.97 (0.83-1.14)    0.78 (0.63-0.97) 
Total 
cholestero
l (mmol/L)  
- 0.96 (0.90-1.02)    1.05 (0.97-1.14) 
Diabetes 
No 11.0 1   1 1 
Yes 33.1 3.99 (3.32-4.80)   2.03 (1.64-2.53) 1.78 (1.42-2.23) 
Hypertension 
No 7.6 1   1 1 





No 9.9 1    1 
Yes  
31.9 4.29 (3.68-5.00)    1.51 (1.21-1.88) 
*significant associations are marked bold. 
  




Figure 1: Changes in prevalence (weighted) of CKD EPI serum creatinine eGFR<60 by age and gender 2009/10-2016  
Figure 2: Changes in prevalence (weighted) of albuminuria by age group 2009/10-2016  
